Role of TTV During First-line Immunotherapy Treatment in Patients With Renal Cell Carcinoma

Launched by REGINA ELENA CANCER INSTITUTE · Jun 4, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at a virus called torquetenovirus (TTV) to see if it can help doctors understand how well certain immunotherapy treatments work for patients with advanced kidney cancer, specifically clear cell renal cell carcinoma. The researchers want to see if changes in the amount of TTV in the body during treatment can be used as a sign (or biomarker) to predict how well a patient is responding to the therapy.

To participate in this trial, you need to be at least 18 years old and have been diagnosed with advanced clear cell renal cell carcinoma that requires first-line immunotherapy. If you join, you’ll need to provide consent to participate and follow the study procedures. Throughout the trial, you’ll be monitored to check how your body responds to the treatment and the TTV levels. It’s important to note that certain health conditions or past treatments may prevent you from participating, so discussing your individual situation with the research team is crucial.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients over 18 years of age;
• • Histological diagnosis of clear cell renal cell carcinoma;
• • Evidence of advanced or metastatic disease;
• • Patients diagnosed with metastatic clear cell renal cell carcinoma about to start first-line immunotherapy (ICI + ICI or ICI + TKI);
• • Patients able to comply with the study procedures.
• • Patients who give written informed consent personally or through a witness (study participation and data processing), before any study-specific procedure is started.
• Exclusion Criteria:
• • Previous neoplasms;
• • Previous antineoplastic treatments;
• • Previous steroid treatments;
• • Active viral infections (e.g., HCV, HIV, etc.);
• • Lack of autonomy in adhering to study procedures.